Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
89bio, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ETNB
Nasdaq
2830
www.89bio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 89bio, Inc.
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership
- Feb 6th, 2025 11:45 am
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Feb 3rd, 2025 1:00 pm
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Jan 29th, 2025 3:31 am
Why 89bio Stock Lagged the Market Today
- Jan 28th, 2025 9:59 pm
Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study
- Jan 27th, 2025 9:24 pm
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Jan 27th, 2025 9:12 pm
89bio Provides Business Update and Outlook for 2025
- Jan 13th, 2025 1:00 pm
New Strong Sell Stocks for January 7th
- Jan 7th, 2025 8:17 am
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec 19th, 2024 9:05 pm
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
- Dec 4th, 2024 6:02 pm
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
- Nov 26th, 2024 9:05 pm
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
- Nov 15th, 2024 1:05 pm
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Nov 13th, 2024 4:58 am
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
- Nov 7th, 2024 9:05 pm
89bio to Participate in the UBS Global Healthcare Conference
- Nov 5th, 2024 9:05 pm
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
- Nov 2nd, 2024 4:00 pm
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
- Nov 1st, 2024 8:08 pm
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings
- Oct 18th, 2024 5:01 am
State Street Corp's Strategic Acquisition in 89bio Inc
- Oct 17th, 2024 5:05 pm
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
- Oct 15th, 2024 12:30 pm
Scroll